Observational Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jan 14, 2021; 27(2): 208-223
Published online Jan 14, 2021. doi: 10.3748/wjg.v27.i2.208
Table 3 Inflammatory bowel diseases treatment at enrollment and use of health care resources during the previous 3 years by inflammatory bowel diseases type and by geographic region
CD patients (n = 264)
Southeast (n = 196)
South (n = 34)
Northeast/Midwest (n = 34)
Any CD treatment at enrollment1256 (97.0)189 (96.4)33 (97.1)34 (100.0)
CD treatment at enrollment2
5-ASA derivates39 (14.8)24 (12.2)7 (20.6)8 (23.5)
Biological therapy189 (71.6)140 (71.4)21 (61.8)28 (82.4)
Infliximab106 (40.2)NANANA
Adalimumab78 (29.5)NANANA
Vedolizumab4 (1.5)NANANA
Certolizumab1 (0.4)NANANA
Ustekinumab1 (0.4)NANANA
Immunosuppressors178 (67.4)133 (67.9)18 (52.9)27 (79.4)
Thiopurines165 (62.5)NANANA
Methotrexate14 (5.3)NANANA
Corticosteroids30 (11.4)21 (10.7)2 (5.9)7 (20.6)
Prednisone29 (11.0)NANANA
Hydrocortisone1 (0.4)NANANA
Methylprednisolone1 (0.4)NANANA
Antibiotics14 (5.3)9 (4.6)1 (2.9)4 (11.8)
Any previous CD-related surgery367 (25.4)58 (29.6)8 (23.5)1 (2.9)
CD-related surgeries per patient1.0 [1-5]1.0 [1-5]1.5 [1-3]2.0
Any previous CD-related hospitalization101 (38.3)71 (36.2)14 (41.2)16 (47.0)
CD-related hospitalizations per patient1.0 [1-5]1.0 [1-5]1.0 [1-4]1.0 [1-3]
Previous CD appointments per patient11.0 [1-45]11.0 [1-45]13.5 [4-43]10.0 [1-21]
UC patients (n = 143)Southeast (n = 94)South (n = 21)Northeast/Midwest (n = 28)
Any UC treatment at enrollment1138 (96.5)89 (94.7)21 (100.0)28 (100.0)
UC treatment at enrollment2
5-ASA derivates100 (69.9)60 (63.8)13 (61.9)27 (96.4)
Biological therapy41 (28.7)30 (31.9)7 (33.3)4 (14.3)
Infliximab31 (21.7)NANANA
Adalimumab9 (6.3)NANANA
Vedolizumab2 (1.4)NANANA
Immunosuppressors63 (44.1)41 (43.6)12 (57.1)10 (35.7)
Thiopurines59 (41.3)NANANA
Methotrexate3 (2.1)NANANA
Tacrolimus1 (0.7)NANANA
Corticosteroids26 (18.2)15 (16.0)6 (28.6)5 (17.9)
Prednisone24 (16.8)NANANA
Hydrocortisone2 (1.4)NANANA
Prednisolone2 (1.4)NANANA
Antibiotics7 (4.9)6 (6.4)1 (4.8)NA
Any previous UC-related surgery44 (2.8)4 (4.3)0 (0.0)0 (0.0)
UC-related surgeries per patient2.0 [1-2]2.0 [1-2]--
Any previous UC-related hospitalization28 (19.6)13 (13.8)9 (42.9)6 (21.4)
UC-related hospitalizations per patient1.0 [1-5]1.0 [1-2]2.0 [1-5]1.0 [1-2]
Previous UC appointments per patient10.0 [1-39]10.0 [1-39]14.0 [4-38]9.0 [1-17]
Data are shown as n (%) or median [range]. Percentages were calculated for the total group of patients.
1Any inflammatory bowel diseases treatment ongoing or initiated at the study appointment.
2More than one possible option: patients could have combined treatment.
3The most common surgeries were fistulectomy/anal fistulectomy (20.4% of patients), partial colectomy (12% of patients) and enterotomy and/or enterorrhaphy with suture/resection (12%).
4Two total colectomies and two enterostomy closures.
CD: Crohn’s disease; 5-ASA: 5-Aminosalicylic acid; NA: Not available; UC: Ulcerative colitis.
  • Citation: Zaltman C, Parra RS, Sassaki LY, Santana GO, Ferrari MLA, Miszputen SJ, Amarante HMBS, Kaiser Junior RL, Flores C, Catapani WR, Parente JML, Bafutto M, Ramos O, Gonçalves CD, Guimaraes IM, da Rocha JJR, Feitosa MR, Feres O, Saad-Hossne R, Penna FGC, Cunha PFS, Gomes TN, Nones RB, Faria MAG, Parente MPPD, Scotton AS, Caratin RF, Senra J, Chebli JM. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(2): 208-223
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i2/208.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i2.208